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Abstract: Direct oral anti-coagulants (DOACs) are employed in clinical practice for the prevention
and treatment of recurrent venous thromboembolism and for the prevention of stroke in non-valvular
atrial fibrillation. DOACs directly and reversibly inhibit activated factor X or thrombin and can
interfere with other pathophysiological processes such as inflammation, lipid metabolism, and bone
turnover. We aimed to evaluate the possible effects of DOACs on osteogenesis and angiogenesis.
We treated 34 patients affected by cardiovascular disorders with DOACs; biochemical and molecular
analyses were performed before and after three months of treatment. Circulating progenitors (CPs;
CD34−, CD45−, CD14−, CD73+, CD105+), which share typical bone marrow stem cell (MSCs)
features, were harvested from peripheral blood of the study subjects to monitor the expression of
osteogenesis-related genes RUNX2 and SPARC. Human umbilical vein endothelial cells (HUVECs)
were used to probe angiogenesis-related VEGF, CD31, and CD105 gene expression. We performed
co-culture experiments using a commercial human mesenchymal stem cells line (hMSCs) obtained
from bone marrow and HUVECs. Clinical parameters related to bone metabolism, coagulation,
renal and liver function, and the lipid profile were evaluated. Values of the C-terminal telopeptide
type I collagen (CTX) increased after the treatment. We found a significant increase in osteogenesis
marker gene expression in CPs after three months of anticoagulant therapy. An increase in the
RUNX2 expression determinant alone was detected instead in hMSCs co-cultured with HUVECs in
the presence of treated patients’ sera. The VEGF, CD31, and CD105 marker genes appeared to be
significantly upregulated in HUVECs co-cultured with hMSCs in the presence of treated patients’ sera.
Under these conditions, new vessel formation increased as well. Our results highlight an unexpected
influence of DOAC therapy on osteogenic commitment and vascular endothelial function promotion.
Keywords: anticoagulants; circulating progenitors; osteogenesis; gene expression
1. Introduction
Direct oral anti-coagulants (DOACs) are direct and selective inhibitors of specific factors of
the coagulation cascade [1]. Those currently in use are three activated factor X (AFX) inhibitors,
rivaroxaban, apixaban, and edoxaban, and a thrombin inhibitor, dabigatran. DOACs are often
referred to as non-vitamin K oral anti-coagulants (NOACs) to emphasize their distinction from vitamin
K antagonists (VKAs), whose main exponent is warfarin. The VKA mechanism of action in the
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coagulation cascade is based on antagonizing vitamin K, an essential cofactor for γ-carboxylation of
factors II, VII, IX, and X [2].
DOACs are indicated for the prevention and treatment of recurrent venous thromboembolism
(VTE) and for the prevention of stroke and systemic embolization in patients with non-valvular atrial
fibrillation (NVAF). Patients who underwent mechanical valve prostheses or suffered from moderate
to severe mitral stenosis are excluded from the treatment [2,3]. Thromboembolic disease can occur
both in the arterial and the venous system with different characteristics in terms of the determining
factors, thrombus morphology, and associated diseases.
Factor Xa and thrombin have been shown to play fundamental roles in coagulation and in other
processes, mainly through the activation of protease-activated receptor (PARs), a family of proteolytic
cleavage-activated receptors found in almost all tissues and cell types [4]. Thrombin-PAR-1 interaction
activates the signaling axis involved in actinic cytoskeleton modifications of endothelial cells, thus
contributing to endothelial barrier disruption and increased permeability [5]. In patients suffering
from vascular disease, factor Xa modifies the expression levels of oxidative stress-induced proteins,
thereby affecting aerobic mitochondrial metabolism [6]. Through the stimulation of PAR-1 and -2 and
the activation of insulin-like growth factor binding protein 5 (IGFBP5) and p53, factor Xa induces a
senescent phenotype and the expression of pro-inflammatory molecules in the smooth muscle cells of
the vascular wall [7]. Due to their key role in various signaling pathways in both vascular and immune
systems, factor Xa and thrombin appear to participate in atherosclerosis and plaque progression as
well as in remodeling and fibrosis processes [7].
Consequently, the ability of DOACs to act as inhibitors of these non-hemostatic functions
of factor Xa and thrombin has been tested. The role of rivaroxaban in promoting angiogenesis
has been demonstrated. Increased levels of vascular endothelial growth factor (VEGF) and nitric
oxide synthase (eNOS) were detected in animal models in response to conditions of relative tissue
ischemia [8]. Apixaban also appears to influence vasomotor function by increasing vasodilation
through PAR-2-induced NO synthesis [9]. Various studies in animal models seem to confirm that
DOACs attenuate endothelium interactions with leukocytes and platelets, which represent the first step
in the inflammatory and atherothrombotic process in microcirculation [10]. The same stabilizing effect
on atherosclerotic lesions and inhibition of vascular pathology progression have been documented
in ApoE knockout mice, characterized by high levels of very low density lipoprotein (VLDL) and
low density lipoprotein (LDL). A reduction in plaque size and inherent oxidative and inflammatory
phenomena with a concomitant reduction of nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-κB), matrix metallopeptidase 9 (MMP-9), vascular cell adhesion protein 1 (VCAM-1),
and tumor necrosis factor α (TNFα) were reported [10]. In vitro treatment of endothelial progenitor
cells with an activated factor X inhibitor increased the activity of eNOS and the expression of key
angiogenic growth factors, such as VEGF. Microscopic observations showed the increased ability of
endothelial progenitors to produce vascular tubular structures, promoting endothelial cell functions in
terms of repair and regeneration and possible pro-angiogenic properties derived from the inhibition of
factor Xa [8].
Modulation of human mesenchymal stem cells via crosstalk with endothelial cells was
demonstrated by Bidarra et al. [11], who demonstrated that human mesenchymal stem cells (hMSCs)
co-cultivation with human umbilical vein endothelial cells (HUVECs) increased proliferation and
osteogenic differentiation. Therefore, osteogenesis and angiogenesis are strongly related processes [12].
RUNX2 knock out has been associated with reduced VEGF synthesis and impaired vascular invasion
during cartilage differentiation [13]. RUNX2 transcription factor is present in endothelial cells as
well as in vascular smooth muscle cells during in vivo angiogenesis [14,15]. Therefore, on the
basis of pleiotropic effects and considering that osteogenesis and angiogenesis are related processes,
we hypothesized that DOACs might interfere with bone formation.
To gain a more in-depth knowledge of anticoagulant treatment effects on bone and vasculature,
we evaluated the modulation of gene expression profiles induced by DOACs in circulating progenitor
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cells. We analyzed the effects of crosstalk between endothelial cells and marrow stem cells (MSCs) in
the presence of sera collected from patients during the treatment with DOACs.
2. Experimental Section
2.1. Subjects
The study was conducted at Verona University Hospital, Italy. We recruited 34 patients with a
mean age of 79 ± 9 years from January to June 2018. Of the 34 patients, 23 were sourced from the
Department of Internal Medicine for Atherothrombotic and Degenerative Diseases, and 11 patients
were selected by the Stroke Unit. Written informed consent was obtained from all participants, and the
study was approved by the Ethical Committee of Azienda Ospedaliera Universitaria Integrata of
Verona, Italy (No. 1538).
Of the 34 enrolled, 18 patients presented a previous diagnosis of non-valvular atrial fibrillation
(NVAF), 8 patients were under observation after the first detection of deep vein thrombosis (DTV)
of the lower limbs or pulmonary embolism (PE). The last group of 8 patients was diagnosed with
ischemic stroke. Among these, a diagnosis of NVAF, previously unknown, was confirmed in 3 patients
during the investigations to attest to the cardioembolic etiology of the ischemic stroke that had led
to hospitalization.
A summary of the previously assumed therapy, classifying patients according to the underlying
disease, is provided in Table 1.
Table 1. Previously prescribed therapies in patients classified according to the underlying disease.
The largest group of patients reported warfarin treatment for NVAF. NVAF non-valvular atrial
fibrillation, VTE venous thromboembolism, ASA acetylsalicylic acid.
Disease Previous Therapy No. of Patients
NVAF
No treatment 0
Warfarin 12
Enoxaparin 2
ASA 1
VTE
No treatment 3
Warfarin 2
enoxaparin/fondaparinux 3
ASA 0
Ischemic stroke
No treatment 3
Warfarin 2
Enoxaparin 0
ASA 6
A 3-month follow-up was scheduled for all patients enrolled in the study.
2.2. Biochemical Parameters
At the beginning of direct oral anticoagulant therapy and after 3 months, the following fasting
blood parameters were evaluated: blood count, coagulation, lipid profile, renal and liver function,
and phospho-calcic parameters. We considered the hemoglobin concentration, hematocrit, platelet
count, prothrombin time- international normalized ratio (PT-INR), activated partial thromboplastin
time (aPTT), total cholesterol, high density lipoprotein (HDL), triglycerides, creatinine, aspartate
tansaminase (AST), alanine transaminase (ALT), calcemia, C-terminal telopeptide type I collagen
(CTX), and vitamin D concentration. Using the Cockroft–Gault formula, the glomerular filtration rate
(eGFR) was estimated, and the serum LDL fasting serum was calculated using the Friedwald formula.
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2.3. Isolation of Circulating Progenitor Cells
Before and after 3 months of DOAC treatment, each patient underwent peripheral venous blood
sampling, and CPs—cells with typical bone MSCs features—were collected, as reported previously [16].
CPs were isolated from 25 mL of heparinized blood by a depletion method, including two Ficoll
procedures to remove hematopoietic cells using the antibodies cocktail. Firstly, peripheral blood
mononuclear cells (PBMCs) were obtained by a gradient centrifugation at 800× g for 30 min at 20 ◦C
(first Ficoll procedure). Then, to remove unwanted hematopoietic cells, a Rosette-Sep antibody cocktail
was used with 5 mL of whole blood mixed with the PBMCs obtained by the first Ficoll; the antibody
cocktail was incubated with samples for 20 min at room temperature. Then, a second Ficoll procedure
was performed to remove the unwanted CD3, CD14, CD19, CD38, and CD66b positive cells crosslinked
to red blood cells (glycophorin A).
Generally, CPs originating osteogenic, condrogenic, and adipogenic cells are defined as CD34−,
CD45−, CD14−, CD73+, CD105+ cells [17,18]. Therefore, we evaluated their phenotype by analyzing
gene expression for CD3, CD14, CD19, CD45,CD34, CD73, and CD105 markers, as reported
previously [19]. This method allows the analysis of the phenotype of cells isolated by stringent
purification strategies, as previously described [20].
2.4. RNA Extraction and Reverse Transcription
RNA was extracted using the Q RNA Assay Mini-Kit (Quiagen, Hilden, Germany) with DNase
I treatment. The obtained RNA was quantified by measuring absorbance at 260 nm, and the purity
was checked by measuring the 260/280 absorbance ratio. First-strand complementary DNA (c-DNA)
synthesis was performed using the First Strand cDNA Synthesis Kit (GE Healthcare, Little Chalfont,
UK) using random hexamers (GE Healthcare, Little Chalfont, UK) according to the manufacturer’s
protocol. The product was then aliquoted in equal volumes and stored at −80 ◦C until use.
2.5. Real Time PCR (RT-PCR)
PCR was performed using Taqman Universal PCR Master mix (Thermofisher Corporation,
Waltham, MA, USA). Pre-designed gene-specific primers and probe sets for each gene (osteogenic
gene markers: RUNX2, Hs00231692_m1; SPARC, Hs00234160_m1; endothelial gene markers; VEGF,
Hs00900055_m1; CD31, Hs01065279_m1; CD105, Hs00923996_m1; hematopoietic gene markers:
CD3, Hs00174158_m1; CD14, Hs02621496-s1; CD19, Hs00174333_m1; CD45, Hs00174541_m1; CD34,
HS00156373_m1; mesenchymal gene marker CD73, Hs00159686_m1: CD105, Hs00923996_m1 in
CD34 negative cells; and housekeeping genes: ACTB, 4326315E, and B2M, 4326319E) were obtained
from Assay-on-Demand Gene Expression Products (Thermofisher Corporation, Waltham, MA, USA).
Real-time (RT) amplifications included 10 min at 95 ◦C (AmpliTaq Gold activation), followed by 40
cycles at 95 ◦C for 15 seconds, and finally at 60 ◦C for 1 min. Thermocycling and signal detection
were performed with an ABI Prism 7300 Sequence Detector (Applied Biosystems; Foster City, CA,
USA). Ct values for each reaction were determined using TaqMan SDS analysis software (Applied
Biosystems; Foster City, CA, USA), as reported previously [19]. The analyses were performed by using
the 2−∆∆CT method. This method allows for the calculation of the relative gene expression levels
between different samples [21].
2.6. Cell Cultures and Co-Cultures Preparation
Bone marrow-hMSCs (Heidelberg, Germany) were cultured and induced to proliferate in MSC
growth medium (MSCGM; Cologne, Germany). The osteosarcoma cell line MG63 and normal human
epidermal melanocytes (NHEM) (used as low expressing cells) were purchased from American Type
Culture Collection (ATCC CTRL-1619TM; Rockville, MD, USA) and cultured in the presence of RPMI
medium. Cell lines were cultured under a humidified atmosphere of 5% CO2 in the presence of
growth medium (MSCGM or RMPI 1640 (Sigma-Aldrich; St. Louis, MO, USA) containing 10% fetal
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bovine serum (FBS; Sigma-Aldrich; St. Louis, MO, USA) and supplemented with antibiotics (1%
penicillin/streptomycin) and 1% glutamine.
Primary HUVEC at passage 10 was provided from Professor Bazzoni of the University of Verona,
Italy. Untreated cells were used as the positive control. Cells were cultured in a 75 cm2 culture flask
coated with Matrigel (Corning Incorporated; New York, NY, USA) in the presence of M200 medium
and 10% low serum growth supplement (LSGS) (Thermo Fisher Scientific, Waltham, MA, USA) under
a humidified atmosphere of 5% CO2. Co-cultured cells were arranged in a 6-well Transwell plate with
0.4 µm pores (Corning Incorporated; Corning, NY, USA). HUVECs were cultured in the presence of
10% sera from patients enrolled in the study. Sera were obtained from 6 mL of peripheral venous
blood by centrifugation and stored at −80 ◦C until use. Co-cultures of MSCs and HUVECs with a
1:1 ratio were prepared and treated in the presence of 10% of sera collected before and after 3 months
of treatment.
2.7. Immunofluorescence
Transwell membranes were cut using a scalpel and washed three times in 1× phosphate buffered
saline (PBS). Membranes were incubated for 1 h at room temperature with 10% goat serum. RUNX2
antibody (Novusbio, Centennial, CO, USA) at 1:100 dilution was incubated in agitation overnight at
room temperature. For signal detection, Alexa Fluor 488 (Life Technologies, Carlsbad, CA, USA) and
ProLong™ Gold Antifade Mountant with 4’,6-diamidin-2-fenilindolo (DAPI) for nuclei counterstaining
(Life Technologies, Carlsbad, CA, USA) were used. Photos were acquired using a Leica DM2500
microscope (Leica Microsystems, Wetzlar, Germany) at 10, 20, 40, and 63× magnifications.
2.8. Alizarin Staining
After 21 days of culture in specific MSCGM medium, cells were fixed with 70% ethanol and
subsequently rinsed with deionized water. Cells were then treated for 5 min with 40 mM Alizarin red
S at pH 4.1 and again washed with PBS for 15 min. For staining technique control, we used MG63 cells.
MG63 cells cultured with 125 µM of ascorbic acid were employed as the positive staining control for
calcium deposition. We used undifferentiated hMSCs as the negative control for calcium deposition.
2.9. Net-Like Formation Assay
Six-well Transwell plates with 0.4 µm pores (Corning Incorporated, Corning, NY, USA) were
used. HUVEC cells were plated in the chamber, and MSC cells were plated in the inserts and cultured
with their specific culture medium at a 1:1 ratio, both in duplicate. After 7 days, the inserts were
removed and stained with Mayer’s hematoxylin (Sigma Aldrich; St. Louis, MO, USA) for 1 min and
photographed at 5× magnification using a Leica DMi1 microscope (Leica Microsystems, Wetzlar,
Germany). Completely enclosed spaces were considered to quantify net-like structures, as previously
reported [22].
2.10. Statistical Analysis
All data were normally distributed and are expressed as mean ± standard deviation.
Differences between groups were tested for significance using Student’s T-test and multiple ANOVA
measurements. Statistical significance was considered for a p-value of <0.05. Statistical analyses were
performed using SPSS for Windows, version 22.0 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Clinical and Biochemical Data
Table 2 shows the baseline anthropometric and biochemical characteristics of the patients
enrolled in the study compared to those observed three months after the beginning of direct oral
anticoagulant therapy.
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Table 2. Biochemical parameters detected before and after three months of direct oral anti-coagulant
(DOAC) therapy. Continuous variables are expressed as mean ± SD; n.s (not statistically significant).
Parameter Baseline 3 Months p-Value
Hemoglobin (g/dL) 13.4 ± 1.7 13.1 ± 2.0 n.s.
Hematocrit, (%) 41 ± 5 40 ± 6 n.s.
Platelets, (109/L) 209 ± 71 217 ± 65 n.s.
PT-INR 1.71 ± 0.65 1.27 ± 0.23 n.s.
aPTT, ratio 1.08 ± 0.20 1.18 ± 0.44 n.s.
Cholesterol, (mg/dL) 160 ± 30 162 ± 38 n.s.
HDL, (mg/dL) 52 ± 14 53 ± 14 n.s.
Triglycerides, (mg/dL) 111 ± 42 105 ± 30 n.s.
LDL, (mg/dL) 79 ± 24 83 ± 33 n.s.
Creatinine, (mg/dL) 1.09 ± 0.44 1.16 ± 0.45 n.s.
eGFR, (mL/min) 61 ± 22 57 ± 21 n.s.
AST, (U/L) 24 ± 14 19 ± 7 n.s.
ALT, (U/L) 23 ± 16 18 ± 8 n.s.
Calcium, (mg/dL) 8.7 ± 0.3 9.4 ± 0.4 n.s.
Vitamin D (25-OH), (ng/mL) 17 ± 7 25 ± 14 n.s.
CTX, (ng/mL) 0.31 ± 0.09 0.36 ± 0.12 <0.05
Note: PT-INR, prothrombin time-international normalized ratio; aPTT, activated partial thromboplastin time; HDL,
high-density lipoproteins; LDL, low-density lipoproteins; eGFR, estimated glomerular filtration rate; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; CTX, C-telopeptide of type I collagen.
A significant increase in CTX emerged after three months of treatment with DOACs (CTX at
first visit: 0.31 ± 0.09 ng/mL; at three months: 0.36 ± 0.12 ng/mL; p < 0.05), if it remained in the
normal range. No statistically significant changes in the other biochemical parameters examined
were observed.
On average, after three months of treatment with DOACs, hemoglobin levels tended to decrease.
The result is not statistically significant and can be traced to the effect of anticoagulant therapy. None of
patients experienced bleeding or other complications related to anticoagulant treatment. Data collected
showed PT-INR levels above the normal range at the end of the observational period but still lower
than the initial values. PT-INR values at first visit were influenced by the fact that 16 of the 34 selected
patients previously were treated with warfarin.
Notably, there was an improvement in vitamin D levels measured at the follow-up visit (vitamin
D at first visit: 17 ± 7 ng/mL; at three months: 25 ± 14 ng/mL), but levels remained slightly low.
All patients in whom hypovitaminosis D was initially found were given the indication to perform
supplementation with cholecalciferol 50,000 U.I./month.
To assess the role of the underlying disease, we also tested for the presence of any differences
in blood parameters at baseline and after three months in patients diagnosed with NVAF compared
with those with VTE or ischemic stroke. A significantly higher level of baseline PT-INR was observed
in patients receiving direct oral anticoagulant therapy for NVAF compared with those presenting
acute thromboembolism or cerebral ischemic event (Table 3). These data indicate a trend in preferring
DOACs for patients diagnosed with thromboembolism or acute ischemic stroke. Warfarin still seems
to be the first choice in clinical practice for patients with NVAF. At three months, no statistically
significant difference could be seen between groups of patients with different underlying diseases.
Table 3. Baseline PT-INR in patients classified according to the underlying disease.
Parameter NVAF VTE Ischemic Stroke p Value
PT-INR (baseline) 2.2 ± 0.5 1.5 ± 0.5 1.3 ± 0.3 <0.05
PT-INR prothrombin time-international normalized ratio, NVAF non-valvular atrial fibrillation, VTE venous
thromboembolism.
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3.2. DOACs Enhance Osteogenic Commitment
The percentage of CD105+ and CD73+ cells was higher that 60% with low expression of CD14,
CD45, and CD34 markers. CPs collected before and after three months of treatment showed the same
cluster differentiation markers expression (Table 4).
Table 4. Cluster differentiation (CD) markers expression was similar in circulating progenitors
harvested before and after three months of DOAC treatment. n.s (not statistically significant).
Cluster Differentiation Transcript Pre DOACS Post DOACS p-Value
CD105 65 ± 0.6% 64% (±0.5) n.s
CD 73 73% (±0.3) 72 (±0.2) n.s
CD3 0% 0% n.s
CD14 0.3% (±0.04) 0.4% (±0.06) n.s
CD19 0% 0% n.s
CD45 1.6% (±0.3) 1.8% (±0.4) n.s
CD34 low level low level n.s
The analysis of the osteogenic gene expression in CPs demonstrated a significant increase in the
expression of RUNX2 (5.5-fold increase, p < 0.05) and SPARC (2.6-fold increase, p < 0.05) three months
after the beginning of direct oral anticoagulant therapy (Figure 1).
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Figure 1. 2 and ARC gene expres ion in circulating progenitors before and after thre months
of DOAC treatment. * p < 0.05.
Expression of osteogenic genes was analyzed in MSCs when co-cultured with HUVEC and in the
presence of patients’ sera before and after three months of DOAC treatment. We observed a higher
level of mRNA (Figure 2A) and protein (Figure 2B) expression of transcription factor RUNX2 in the
presence of patients’ sera after treatment. The expression of genes related to osteoblastic maturation,
such as SPARC, ALP, and SPP1 (Figure 2C), as well as the calcium deposition evaluated using Alizarin
red staining (Figure 2D), did not change.
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Figure 2. (a) RUNX2 gene expression and (b) protein expression in hMSCs co-cultured with human
umbilical vein endothelial cells (HUVEC) and patients’ sera before (pre) and after (post) three months
of DOAC treatment. (c) SPARC, SPP1, and ALP expression and (d) Alizarin red staining in the same
setting of cells to evaluate osteogenic maturation; neg [wo RUNX2 antobody; (b)] [undifferentiated
hMSC; (d)]; pos (ascorbic acid treated-MG63 cells). Magnification in (b) 10 × and (d) 4×. * p < 0.05.
3.3. DOACs Increase Expression of Key Angiogenic Markers n Presence of MSCs
In HUVECs cultured in the presence of sera collected from patients enrolled in the study, the gene
expressions of VEGF, CD31, and CD105 were analyzed. As we analyzed the relative gene expression
by using the 2−∆∆CT method, we considered the untreated HUVECs as the calibrator (baseline
levels; value 1). We compared the expression levels of all samples with a low-level expressing cell line
(the normal melanocytes cell line NHEM). Compared with baseline levels, VEGF marker expression
increased when cultured with sera of patients after three months of direct oral anticoagulation treatment
(Figure 3). However, VEGF expression was higher in HUVEC co-cultured with MSCs and in the
presence of sera from patients after the treatment (Figure 3).
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Similarly, the expression of CD105 increased in HUVEC in the sera of patients after three months
of treatment (Figure 4); this effect was more remarkable in HUVEC co-cultured with MSCs (Figure 4).
The expression of CD31 was higher in HUVEC in the presence of sera of patients after three months of
treatment only when co-cultured with MSCs (Figure 4).
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patients before (pre) and after (post) three months of DOAC treatment. The sera (pre or post treatment)
were added in HUVEC co-cultured with MSCs. NHEM: normal melanocytes used as low expressing
cells. * p < 0.05; ** p < 0.01; *** p < 0.005.
Enhanced angiogenesis after three months of treatment was confirmed by the increased number
of net-like formations when HUVECs were co-cultured with sera of patients (Figure 5).
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Figure 5. (a) Net-like formations originated from HUVECs co-cultured with hMSCs without (no sera
added to the medium; untreated HUVEC) or with sera collected from patients before (pre) and after
three months of DOAC treatment (post). Magnification 10×; insert magnification 40×; (b) the graph
shows the net-like formations number calculated on the above samples.
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4. Discussion
Growing interest is emerging in the supposed involvement of DOACs in regulating vascular
endothelial function.
In HUVEC cultures and animal models, factor Xa appears to be characterized by anti-angiogenic
properties, mediated by the activation of PAR-1, and supported by endothelium stabilizing factors
secreted by pericytes, fibroblasts, and the smooth muscle cells of the vessel wall.
With regard to endothelial function, the data in the present study are in line with previous
evidence. In HUVECs treated with the sera of the enrolled patients three months after the beginning of
DOACs therapy, we observed increased expression of VEGF and CD105 markers, which are involved
in the processes of vascular renewal and the maintenance of vessel wall integrity. Vascular endothelial
growth factor (VEGF) family members are involved in angiogenesis, having VEGFR as their specific
tyrosine-kinase receptor located on the cell surface [23]. CD105, also known as endoglin, is part
of the TGF-β receptor complex. The absence of endoglin does not affect the formation of the first
endothelial networks (mediated by VEGF), but endoglin is essential for the efficient organization
of mature vascular structures [23]. Expression of the CD31 marker, conversely, did not change in
HUVECs treated with patients’ sera after three months of DOACs. CD31, encoded by the PECAM1
gene, is normally expressed by endothelial cells and contributes to the maintenance of the permeability
barrier [24]. However, expression levels of VEGF, CD105, and CD31 markers increased considerably
when HUVECs were co-cultured with MSCs. These findings demonstrate that DOACs improve
endothelial function by acting on HUVECs-MSCs crosstalk. Importantly, MSCs have been shown to
release several exosomes containing microRNAs (miRNAs), which can be transferred to endothelial
cells, promoting angiogenesis [25].
With respect to the role of anticoagulants in the processes of mineralization and vascular
calcification, the mechanisms linked to the inhibition of vitamin K by VKAs are well known [26].
In osteoblastic cell cultures, warfarin was confirmed to inhibit the differentiation process through the
reduction of alkaline phosphatase (ALP), Collagen 1A1 (COL1A1), Osteocalcin, Osterix, genes expression,
and the interruption of RUNX2 transcriptional activity [27]. VKAs treatment could therefore result
in an increased risk of osteoporosis, vascular calcification, and blockage of vessels renewal [28].
Comparing the effects of thrombus prophylaxis with various anticoagulant drugs, enoxaparin and
warfarin tend to inhibit gene expression of osteogenic differentiation markers, whereas the FXa
inhibitor rivaroxaban, by acting on IGF2, promotes osteoblastic survival. Our data confirm the effects
of rivaroxaban in promoting osteogenic commitment. Analyzing RUNX2 and SPARC expression
in circulating progenitors, a statistically significant increase was observed at the end of the study.
Therefore, even if additional studies are needed, our data suggest an influence of DOACs in regulating
bone forming processes; this aspect could suggest a further distinction from VKAs. After three months
of treatment with DOACs, a significant increase in CTX was observed in patients, although within the
normal range. Therefore, we suppose that DOACs promote bone resorption as well. Bone formation
and resorption are coupled processes. Further studies should investigate skeletal system-related
molecular pathways affected by DOACs.
Our data regarding increased RUNX2 gene expression were confirmed in co-cultures of MSCs
and HUVECs treated in the presence of sera collected from patients after DOAC treatment. However,
despite an increased expression of RUNX2, the expression of genes such as SPARC, SPP1, and ALP,
which are related to osteogenic maturation, did not change.
The increased expression of RUNX2 uncoupled from a subsequent upregulation of the osteogenic
maturation markers suggests that MSCs co-cultured with HUVECs are halted in an undifferentiated
state by DOACs. This is an important finding since it suggests how the calcification process may be
avoided when MSCs are tightly in contact with endothelial cells.
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5. Conclusions
Our results suggest a possible influence of direct oral anticoagulant therapy not only on the
coagulation system but also on bone metabolism and the endothelial and restorative functions of
the vessel wall. The latter is of particular interest, as DOAC-treated pathological conditions include
endothelial dysfunction, alteration of the hemostatic balance, and hypercoagulability. Further studies
on a larger patient sample for a longer observational period might confirm the specific properties of
DOACs, suggesting new perspectives for their targeted use.
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